Dupixent Lymphoma Lawsuit – CTCL, Mycosis Fungoides, and Sezary Syndrome Cancer Claims

If you or a loved one were diagnosed with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, or Sezary Syndrome after using Dupixent, you may be entitled to compensation.

Dupixent (generic name dupilumab) is a biologic medication prescribed for eczema, asthma, nasal polyps, and chronic inflammatory skin and lung conditions. While it has helped many patients manage symptoms, reports and scientific literature have raised concerns about a potential link between Dupixent and cutaneous T-cell lymphomas — rare but serious cancers of the immune system that primarily affect the skin.

At the Law Offices of Jason Turchin, our product liability lawyers can investigate potential Dupixent lymphoma lawsuits on behalf of patients nationwide. You may be able to bring a claim if you developed CTCL, Mycosis Fungoides, or Sezary Syndrome after taking Dupixent.

Call (800) 337-7755 or use our live chat for a free, confidential consultation. You pay nothing unless we recover money for you.

What Is Dupixent?

Dupixent is a biologic immunomodulator approved by the FDA and manufactured by Regeneron Pharmaceuticals and Sanofi Genzyme. It’s prescribed for conditions such as:

• Moderate-to-severe atopic dermatitis (eczema).
• Asthma not adequately controlled by inhalers.
• Chronic rhinosinusitis with nasal polyps (CRSwNP).
• Eosinophilic esophagitis (EoE).

According to the information released, it works by blocking two key inflammatory proteins — IL-4 and IL-13 — to reduce immune-driven inflammation.

While Dupixent may not be a traditional immunosuppressant, it allegedly can alter how the immune system functions. Researchers have begun questioning whether those immune changes may, in rare cases, allow T-cell lymphoma cells to develop or proliferate.

Allegations Linking Dupixent to CTCL and Other Skin Lymphomas

Cutaneous T-cell lymphoma (CTCL) is a group of non-Hodgkin lymphomas that affect the skin’s T-cells. The two most common forms are:

• Mycosis Fungoides – a slowly progressing cancer that often starts as red, scaly patches or plaques that resemble eczema.
• Sezary Syndrome – a more aggressive form involving malignant T-cells in the blood, skin, and lymph nodes.

Alleged Dupixent Connection

Some dermatologists and oncologists have reported cases in which patients treated with Dupixent for eczema or other inflammatory skin conditions later developed CTCL or Sezary Syndrome.

The concern is twofold:

1. Masking of symptoms – Dupixent can temporarily improve itching and redness, potentially delaying the diagnosis of an underlying lymphoma.
2. Immunologic changes – by blocking interleukin pathways, Dupixent may alter immune surveillance mechanisms that normally help detect or suppress malignant T-cells.

Published Case Reports and Studies

• 2019 Journal of the American Academy of Dermatology (JAAD): several cases described patients misdiagnosed with eczema who were later found to have CTCL after months of Dupixent therapy.
• 2020–2024 Reports: dermatologists have continued to identify CTCL and Sezary Syndrome diagnoses occurring after initiation of Dupixent, sometimes following apparent initial improvement.
• Post-marketing surveillance data from the FDA’s Adverse Event Reporting System (FAERS) show a number of lymphoma-related reports involving Dupixent.

Although definitive causation has not been proven, the pattern has prompted lawsuit investigations alleging Regeneron and Sanofi failed to warn patients and doctors adequately about this potential risk.

Symptoms That Could Indicate CTCL or Related Lymphomas

Signs that warrant medical evaluation include:

• Persistent or worsening itchy, scaly, or patchy skin lesions unresponsive to treatment.
• Thickened plaques or raised skin areas that change color.
• Swollen lymph nodes in the neck, groin, or underarms.
• Hair loss in affected patches.
• Redness covering large areas of skin (erythroderma).
• Fatigue or night sweats.
• In Sezary Syndrome, abnormal blood tests showing malignant T-cells.

If you experienced these symptoms after starting Dupixent, consult your dermatologist or oncologist immediately.

What Is the Basis of a Dupixent Lymphoma Lawsuit?

Plaintiffs in potential Dupixent lawsuits may allege that Regeneron and Sanofi:

• Failed to warn doctors and patients about the possibility of lymphoma or delayed diagnosis.
• Negligently marketed Dupixent as safe for long-term use without adequate post-marketing surveillance.
• Did not conduct sufficient studies to evaluate cancer risks in patients with chronic skin inflammation.
• Downplayed reports of CTCL and related lymphomas in clinical data.

These lawsuits would aim to recover compensation for individuals diagnosed with CTCL, Mycosis Fungoides, Sezary Syndrome, or other lymphomas after using Dupixent.

Potential Damages in a Dupixent Lymphoma Lawsuit

If you developed lymphoma after Dupixent use, you may be eligible to seek compensation for:

• Medical expenses – diagnostic tests, biopsies, oncology treatments, chemotherapy, radiation, or immunotherapy.
• Future medical costs – ongoing monitoring or relapse treatment.
• Lost wages – income lost during illness and treatment.
• Loss of earning capacity – if cancer impacts your ability to work long-term.
• Pain and suffering – physical pain, anxiety, and emotional trauma.
• Loss of consortium – harm to spousal relationship or family life.
• Wrongful death damages – for families of deceased victims.

How to Qualify for a Dupixent Lymphoma Lawsuit

You may qualify if:

1. You were prescribed Dupixent (dupilumab) for eczema, asthma, nasal polyps, or another approved condition.
2. You used the medication for an extended period (months or years).
3. You were later diagnosed with:
   • Cutaneous T-cell lymphoma (CTCL).
   • Mycosis Fungoides.
   • Sezary Syndrome.
4. You had no prior history of lymphoma or related malignancy.

Our legal team can review your medical and prescription records to determine whether you may be eligible to file a claim.

Evidence That Can Strengthen Your Claim

• Medical records documenting Dupixent prescriptions, dosing, and duration.
• Pathology reports confirming CTCL or related diagnosis.
• Dermatology notes showing symptom progression during Dupixent use.
• FDA or manufacturer correspondence referencing your case.
• Witness statements or caregiver observations.

Preserving this documentation is crucial. Even if you no longer have the medication packaging, we can often obtain prescription histories directly from pharmacies or healthcare providers.

Dupixent Manufacturer Responsibility

Under U.S. product liability law, drug manufacturers must generally ensure that their products are:

1. Safe when used as directed.
2. Properly tested to identify foreseeable risks.
3. Labeled with adequate warnings of potential side effects.

If Regeneron and Sanofi knew, or should have known, that Dupixent could contribute to or mask lymphoma, and failed to issue timely warnings, they could be held financially responsible for resulting injuries.

FDA Status and Warnings

As of early November 2025, the FDA had not issued a formal black-box warning linking Dupixent to lymphoma, but the agency could still monitor post-marketing reports.

There could be a push for stronger label warnings, emphasizing the importance of biopsy or specialist referral for patients whose eczema fails to improve or worsens while on Dupixent.

Because the condition can mimic eczema, early detection of CTCL can be critical — and patients may not realize Dupixent could obscure the signs.

The Role of Case Reports and Growing Litigation

A growing number of patients nationwide have contacted attorneys after developing Mycosis Fungoides or Sezary Syndrome following Dupixent use.

Some lawsuits could allege that Dupixent:

• Induced malignant T-cell proliferation through immune pathway alteration.

While research is ongoing, the pattern of reported cases has prompted product liability investigations similar to prior drug-related cancer litigations.

What You Should Do If Diagnosed With CTCL After Using Dupixent

1. Seek immediate medical evaluation by a dermatologist or oncologist specializing in CTCL.
2. Document your diagnosis and collect all medical records.
3. Report your case to the FDA’s MedWatch program.
4. Speak with a Dupixent lymphoma lawyer about potential legal rights before time limits expire.

Statute of Limitations

Each state limits the time you have to file a lawsuit. Generally:

• Florida and New Jersey – 2 years.
• New York – 3 years.
• Most other states – 1 to 3 years from the date you discovered or should have discovered the injury.

Because medical diagnosis and causation can take time, it can be essential to contact a lawyer as soon as you suspect Dupixent may be linked to your cancer.

How the Law Offices of Jason Turchin Can Help

• Free case review: we can evaluate your claim and collect necessary records.
• National representation: we handle cases in Florida, New York, New Jersey, and with co-counsel nationwide.
• No fees or costs unless you win: we work on a contingency basis.
• Experience: more than 6,500 product liability and injury claims handled.
• Personalized guidance: we can help coordinate medical record retrieval, expert review, and claim filing.

Our goal is to hold pharmaceutical companies accountable and help victims recover the financial support they deserve if they were at fault.

FAQs – Dupixent Lymphoma Lawsuits

Has the FDA confirmed a Dupixent cancer risk?
No definitive warning exists yet, but the agency is monitoring post-marketing data, and case reports have raised concern about CTCL and related cancers.

Do I qualify if I had eczema before Dupixent?
You may — many lawsuits involve patients initially treated for eczema later found to have CTCL.

How much is a Dupixent lymphoma lawsuit worth?
Every case is different. Settlements or verdicts may vary depending on medical costs, prognosis, and evidence of negligence.

What if my loved one died from CTCL or Sezary Syndrome?
Families may file wrongful-death claims seeking compensation for medical bills, funeral expenses, and loss of companionship.

Speak With a Dupixent Lymphoma Lawyer

If you developed Cutaneous T-Cell Lymphoma, Mycosis Fungoides, or Sezary Syndrome after using Dupixent, you may have a case. Drug companies should be held accountable when their medications cause harm or mask early signs of cancer.

Call the Law Offices of Jason Turchin at (800) 337-7755 or start a live chat to schedule a free consultation. Our Florida product liability lawyers can represent clients nationwide and only get paid if we recover money for you.